The Family Chemist Mounjaro Cost & UK Pricing Guide (2026)

Introduction

If you’re searching for The Family Chemist Mounjaro cost, this guide explains our current UK pricing, what is included in your treatment plan, and how private prescribing works through our GPhC-registered pharmacy.

Mounjaro® (tirzepatide) is a prescription-only medicine licensed in the UK for weight loss and widely prescribed privately for weight management. If you would like to understand how treatment works in more detail, including dosing structure and eligibility, visit our full Mounjaro treatment page. Pricing varies depending on dose strength and whether you are starting treatment or continuing maintenance therapy.

This page provides transparent, up-to-date information so you can make an informed decision.

How Much Does Mounjaro Cost at The Family Chemist?

The cost of Mounjaro at The Family Chemist depends on the prescribed dose and whether you are starting treatment or continuing at a maintenance strength. All pricing reflects a complete regulated prescribing and dispensing pathway, including clinical review, genuine UK-sourced medication, secure delivery, and ongoing support.

Starting Dose (2.5 mg)

Most patients begin treatment at 2.5 mg once weekly for the first four weeks to support safe titration and minimise gastrointestinal side effects.

The 2.5 mg starter pack, which includes injection needles, alcohol swabs and a sharps bin, is priced at £149.99. The 2.5 mg pen without the starter pack is priced at £139.99.

The starter pack is recommended for patients beginning treatment for the first time.

Maintenance Doses (4-Week Supply)

Following the initial phase, the dose may be increased depending on clinical response and tolerability.

Current pricing is as follows:

5 mg – £164.97
7.5 mg – £216.15
10 mg – £238.99
12.5 mg – £259.98
15 mg – £279.98

Higher strengths carry a higher cost due to manufacturer wholesale pricing and supply factors.

Prices are reviewed periodically to reflect wholesale supply costs and service inclusions.

What Is Included in the Price?

When accessing Mounjaro through The Family Chemist, patients receive more than just the medication itself. Each order includes a clinical assessment by a UK-registered prescriber and, where appropriate, a valid private prescription. The medication is dispensed by our GPhC-registered pharmacy using genuine UK-sourced stock supplied through licensed wholesalers.

The service also includes injection needles and a sharps bin for safe disposal where required, alongside free next-day tracked delivery in temperature-controlled packaging.

In addition, patients receive complimentary access to our nutritionist-led support programme. This includes access to our dedicated nutritionist app, educational webinars, structured diet guidance and direct access to prescribers for ongoing support at no additional cost.

There are no hidden subscription requirements. Treatment proceeds only following clinical approval.

Patients exploring medical weight management options may also find it helpful to review our broader guide to regulated GLP-1 treatments and structured weight management pathways.
Learn more about our complete weight loss treatment hub here.

Delivery Information

All Mounjaro orders are dispatched using secure, temperature-controlled packaging to maintain product stability. Delivery is provided via a tracked next-day service. Upon receipt, the medication should be refrigerated at 2–8°C in accordance with manufacturer guidance.

Consultation & Eligibility Criteria

Mounjaro weight loss injections are suitable for adults who meet specific clinical criteria and can safely use the medication under medical supervision.

Patients may be eligible if they have a BMI of 30 kg/m² or above, or a BMI between 27 and 30 kg/m² with a weight-related medical condition such as hypertension, dyslipidaemia, pre-diabetes or cardiovascular disease. For certain ethnic backgrounds where metabolic risk occurs at lower BMI thresholds, eligibility may begin from 27.5 kg/m².

Patients transferring from another provider may also be assessed for continuation of treatment at their current dose.

All patients must complete a medical consultation. Prescriptions are issued only where clinically appropriate and safe.

Can You Get Mounjaro on the NHS?

Yes. Tirzepatide (Mounjaro®) has been recommended by NICE for the management of obesity in certain adults, as well as for specific patients with type 2 diabetes.

However, NHS access for weight management is currently restricted and being introduced gradually through a phased national rollout. Availability depends on local Integrated Care Board (ICB) commissioning decisions and whether specialist weight management services are established in your area.

In England, the standard NHS prescription charge applies (£9.90 per item), unless you are exempt. Prescriptions are free in Scotland, Wales and Northern Ireland.

Because implementation is staged over several years, many patients may not yet be eligible for NHS treatment.

NHS Eligibility for Weight Management

During the initial rollout period, access through primary care is prioritised for individuals with the highest clinical need.

In general, early eligibility requires:

• A body mass index (BMI) of 40 kg/m² or above (adjusted for ethnicity where clinically appropriate), and

• At least four obesity-related health conditions such as:

  • Hypertension

  • Dyslipidaemia

  • Obstructive sleep apnoea

  • Cardiovascular disease

  • Type 2 diabetes

In many regions, prescribing initially occurs within specialist weight management services rather than routine GP appointments. These services provide structured “wraparound” support, including dietary and physical activity guidance alongside medication.

Over time, access may widen as services expand and workforce capacity increases.

Patients should check with their GP or local Integrated Care Board for current eligibility criteria in their area.

Important Clinical Information

Before prescribing tirzepatide, a healthcare professional will discuss expected benefits, possible side effects and whether the treatment is appropriate for you.

Tirzepatide should not be used during pregnancy or breastfeeding and may not be suitable for certain medical conditions. Because the medication can affect gastric emptying, additional contraception may be advised when using oral contraceptive pills. Patients using hormone replacement therapy may be advised to consider transdermal preparations.

Anyone scheduled for surgery should inform their healthcare team if they are taking tirzepatide.

As part of NHS weight management treatment, medication is used alongside dietary changes and increased physical activity.

Private Access Through The Family Chemist

Due to the phased NHS rollout and strict eligibility thresholds, many patients do not currently qualify for NHS treatment or may face delays before services become available locally.

Where clinically appropriate, private treatment offers an alternative pathway. At The Family Chemist, patients complete a structured medical assessment reviewed by a UK-registered prescriber. If suitable, a private prescription is issued and dispensed by our GPhC-registered pharmacy.

Private treatment provides regulated access, transparent pricing, and ongoing clinical oversight without the need to wait for local commissioning expansion.

If you are currently comparing providers, you may wish to
compare weight loss pharmacies in the UK before making a decision.

Patients are encouraged to inform their NHS GP of any privately prescribed medication to support continuity of care.

Why Does the Price of Mounjaro Vary by Dose?

The cost of Mounjaro increases as the prescribed dose increases. This reflects both the clinical structure of treatment and the way the medicine is manufactured and supplied within the UK pharmaceutical market.

The 2.5 mg Initiation Phase

Treatment with Mounjaro usually begins at 2.5 mg once weekly. This starting dose is used for the first four weeks to allow the body to adjust gradually and to reduce the likelihood of gastrointestinal side effects such as nausea.

Beginning at a lower strength is a deliberate safety measure and forms part of responsible prescribing practice. Because this is the lowest available strength, it is typically the least expensive option.

Gradual Dose Escalation

After the initial phase, the dose may be increased stepwise depending on clinical response, weight reduction progress, glycaemic control where relevant, and tolerability.

Not every patient progresses to the highest maintenance dose. Some achieve effective results at intermediate strengths. Dose escalation is guided by clinical need rather than a fixed commercial pathway.

Higher Doses Contain More Active Medicine

One of the most straightforward reasons higher strengths cost more is that they contain a greater amount of the active ingredient, tirzepatide.

Each pen is manufactured at a specific strength, and as the weekly dose increases from 2.5 mg through to 15 mg, the total quantity of active medicine supplied per pen increases accordingly. Higher-strength pens therefore require a larger quantity of drug substance during production, which contributes directly to the wholesale acquisition cost.

The difference in price between strengths is therefore aligned with the amount of medication contained within each pen, not simply the branding.

In addtion, higher dose pens carry a higher wholesale acquisition cost from the manufacturer. As the strength increases from 5 mg up to 15 mg, the supply cost to pharmacies rises accordingly.

Retail pricing reflects:

• Manufacturer pricing structure

• UK wholesale supply costs

• Cold-chain handling requirements

• Regulated dispensing standards

Pricing is therefore aligned with supply cost rather than arbitrary mark-ups.

Manufacturer Pricing and Patent Protection

Mounjaro (tirzepatide) remains under patent protection in the UK and internationally. Patent protection prevents generic versions from being manufactured or sold during the exclusivity period.

Because no generic equivalent is currently available, pharmacies must source the branded product through licensed UK wholesalers. This market exclusivity contributes to the overall pricing structure.

When medicines lose patent protection and generic competition becomes available, prices often decrease. At present, tirzepatide remains a patented, branded treatment.

Regulated Supply and Handling

Mounjaro is a temperature-sensitive injectable medicine that must be stored and transported within strict temperature ranges to maintain stability and effectiveness.

Pharmacies must comply with:

• Licensed wholesaler sourcing requirements

• Cold-chain storage standards

• Regulated dispensing procedures

These regulatory obligations form part of the overall cost of safely supplying the medicine.

Prices are reviewed periodically to reflect wholesale supply costs and service inclusions

Safety & Regulation

Mounjaro (tirzepatide) is a prescription-only medicine (POM) in the United Kingdom. It cannot be supplied without a valid prescription issued by an appropriately qualified healthcare professional.

At The Family Chemist, all patients must complete a structured medical assessment before treatment is approved. Prescriptions are issued only where a UK-registered prescriber determines that Mounjaro is clinically appropriate and safe.

Medication is dispensed through our GPhC-registered pharmacy, using genuine UK-sourced stock obtained from licensed pharmaceutical wholesalers. Storage and dispatch follow strict cold-chain handling standards to maintain product stability.

Patients should always disclose their full medical history and current medication list during consultation.

As with all medicines, side effects can occur. Common reactions include nausea and gastrointestinal discomfort, particularly during dose escalation. Any suspected adverse reactions can be reported via the MHRA Yellow Card Scheme, which monitors medicine safety across the UK.

Patients are encouraged to inform their NHS GP of any privately prescribed medication to ensure continuity of care.

When evaluating providers, patients should prioritise regulation, clinical oversight and transparent prescribing standards.
See our guide to choosing the best online pharmacy for GLP-1 treatment in the UK.